No Data
Stifel Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $127
Stifel analyst Dae Gon Ha maintains $Ultragenyx Pharmaceutical(RARE.US)$ with a buy rating, and maintains the target price at $127.According to TipRanks data, the analyst has a success rate of 46.3%
Stifel Nicolaus Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
Ultragenyx Pharmaceutical Inc. (RARE): Among the Best Mid-Cap Healthcare Stocks To Buy Now
Optimistic Investors Push Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Up 26% But Growth Is Lacking
Ultragenyx to Participate in Investor Conferences in September
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)